Mymoona Akhter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mymoona Akhter has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Mumtaz Alam
Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, 110062, India
25 shared publications Garima Verma
19 shared publicationsMohammad Shaquiquzzaman
Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry School of Pharmaceutical Education and Research, Jamia Hamdard New Delhi India
18 shared publicationsWasim Akhtar
Drug Design and Medicinal Chemistry Laboratory Jamia Hamdard New Delhi India
16 shared publicationsAkranth Marella
Fryer Global Regulatory Solutions and Services Hyderabad Telangana India
15 shared publicationsMohammad Mumtaz Alam
Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, New Delhi, India
15 shared publications
Latest Publications
- 28 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302 (Pt 1) , 118305
Anticancer activity of hydrazones in the last quinquennial period: A special emphasis on various enzyme targets and SAR
- 28 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302 (Pt 1) , 118305
Anticancer activity of hydrazones in the last quinquennial period: A special emphasis on various enzyme targets and SAR
- 10 March 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (1) , 447-462
Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer
Thyroid cancer is the 5th most common type of cancer in the USA. There are various tyrosine kinase inhibitors (TKIs) approved by the US FDA for its treatment but all the approved drugs target receptor tyrosine kinase through different pathways. On 4th May, 2018, a combination of Dabrafenib and Trametinib/Dab-Tra has been approved by US FDA for the treatment of anaplastic thyroid cancer (ATC) that highlights the importance of combination therapy in its treatment. As this combination has some major safety concerns, it creates a need to find an alternative combination. In this manuscript, we have tested the potential of all the combinations possibly made by combining different FDA-approved TKIs against Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) using simultaneous docking. We found that the best combination amongst all is of Pralsetinib and Trametinib/Pra-Tra with a docking score of -14.47 kcal/mol. MD simulation was also carried out and the RMSF and the RMSD of the protein in the bound form suggested that its Model 1 is best amongst all. These results were further strengthened using FEL. The PCA was performed that suggested the structural conformations observed beyond 60 ns are closer to a stable state. The outcome reveals that there are various combinations of TKIs that have the potential to be more efficacious for the treatment of thyroid cancer than Dab-Tra. We also found that a combinatorial approach with TKIs could prove to be better than monotherapy. Further in-vitro and in-vivo studies are required to strengthen the results obtained through in-silico experiment.
- 10 March 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (1) , 447-462
Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer
Thyroid cancer is the 5th most common type of cancer in the USA. There are various tyrosine kinase inhibitors (TKIs) approved by the US FDA for its treatment but all the approved drugs target receptor tyrosine kinase through different pathways. On 4th May, 2018, a combination of Dabrafenib and Trametinib/Dab-Tra has been approved by US FDA for the treatment of anaplastic thyroid cancer (ATC) that highlights the importance of combination therapy in its treatment. As this combination has some major safety concerns, it creates a need to find an alternative combination. In this manuscript, we have tested the potential of all the combinations possibly made by combining different FDA-approved TKIs against Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) using simultaneous docking. We found that the best combination amongst all is of Pralsetinib and Trametinib/Pra-Tra with a docking score of -14.47 kcal/mol. MD simulation was also carried out and the RMSF and the RMSD of the protein in the bound form suggested that its Model 1 is best amongst all. These results were further strengthened using FEL. The PCA was performed that suggested the structural conformations observed beyond 60 ns are closer to a stable state. The outcome reveals that there are various combinations of TKIs that have the potential to be more efficacious for the treatment of thyroid cancer than Dab-Tra. We also found that a combinatorial approach with TKIs could prove to be better than monotherapy. Further in-vitro and in-vivo studies are required to strengthen the results obtained through in-silico experiment.
- 26 March 2024
- Published by Springer Nature
- p. 191-205
A Bioinformatics Insight on Agriculture
- Open Access
- 19 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Identification of expression profiles and prognostic value of RFCs in colorectal cancer
Colorectal cancer (CRC) ranks among the most prevalent cancers globally, with its incidence closely tied to DNA damage. The Replication Factor C (RFC) complexes comprises five protein subunits: RFC1, RFC2, RFC3, RFC4, and RFC5. These RFC complexes play crucial roles in DNA replication, repair pathways, activities post DNA damage, and ATP-dependent processes during DNA synthesis. However, the impact of RFC complexes proteins on CRC prognosis remains unclear. To explore this, we employed a computational analysis approach, utilizing platforms such as the DepMap portal, GEPIA, DAVID Bioinformatics for KEGG pathway analysis, Human Protein Atlas (HPA), STRING, and TIMER. Our results indicate that the mRNA levels of RFC1 and RFC5 were the least expressed among CRC cell lines compared to other RFC complex subunits. Notably, low RFC1 and RFC5 expression was correlated with poor prognosis in terms of CRC patients' overall survival (OS). Immunohistochemical results from the Human Protein Atlas demonstrated medium staining for RFC1, RFC2, and RFC5 in CRC tissues. Furthermore, the low expression of RFC1 and RFC5 showed a significant correlation with high expression levels of miR-26a-5p and miR-636, impacting cell proliferation through mismatch repair, DNA replication, and the nucleotide excision repair pathway. Although the precise functions of RFC1 in cancer are still unknown, our findings suggest that the small-molecule single target, CHEMBL430483, and multiple target molecules could be potential treatments for CRC. In conclusion, the elevated expression of miR-26a-5p and miR-636 targeting RFC1 and RFC5 expression holds promise as a potential biomarker for early-stage CRC detection. These insights provide novel directions and strategies for CRC therapies.
- 19 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-17
Open AccessIdentification of expression profiles and prognostic value of RFCs in colorectal cancer
Colorectal cancer (CRC) ranks among the most prevalent cancers globally, with its incidence closely tied to DNA damage. The Replication Factor C (RFC) complexes comprises five protein subunits: RFC1, RFC2, RFC3, RFC4, and RFC5. These RFC complexes play crucial roles in DNA replication, repair pathways, activities post DNA damage, and ATP-dependent processes during DNA synthesis. However, the impact of RFC complexes proteins on CRC prognosis remains unclear. To explore this, we employed a computational analysis approach, utilizing platforms such as the DepMap portal, GEPIA, DAVID Bioinformatics for KEGG pathway analysis, Human Protein Atlas (HPA), STRING, and TIMER. Our results indicate that the mRNA levels of RFC1 and RFC5 were the least expressed among CRC cell lines compared to other RFC complex subunits. Notably, low RFC1 and RFC5 expression was correlated with poor prognosis in terms of CRC patients' overall survival (OS). Immunohistochemical results from the Human Protein Atlas demonstrated medium staining for RFC1, RFC2, and RFC5 in CRC tissues. Furthermore, the low expression of RFC1 and RFC5 showed a significant correlation with high expression levels of miR-26a-5p and miR-636, impacting cell proliferation through mismatch repair, DNA replication, and the nucleotide excision repair pathway. Although the precise functions of RFC1 in cancer are still unknown, our findings suggest that the small-molecule single target, CHEMBL430483, and multiple target molecules could be potential treatments for CRC. In conclusion, the elevated expression of miR-26a-5p and miR-636 targeting RFC1 and RFC5 expression holds promise as a potential biomarker for early-stage CRC detection. These insights provide novel directions and strategies for CRC therapies.
- 21 September 2023
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 15 (18) , 1669-1685
Synthesis and HDAC1 Inhibitory Activity of a Novel Series of Coumarin-Based Amide Derivatives for Treatment of Cancer
Background: Histone deacetylases (HDACs) play a vital role in the epigenetic regulation of transcription and expression. HDAC1 overexpression is seen in many cancers. Methodology: The authors synth...
- 21 September 2023
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 15 (18) , 1669-1685
Synthesis and HDAC1 Inhibitory Activity of a Novel Series of Coumarin-Based Amide Derivatives for Treatment of Cancer
Background: Histone deacetylases (HDACs) play a vital role in the epigenetic regulation of transcription and expression. HDAC1 overexpression is seen in many cancers. Methodology: The authors synth...
- 28 August 2023
- Published by Springer Nature
- p. 79-96
Chemical Kinetics
- 28 August 2023
- Published by Springer Nature
- p. 45-54
The Distribution Law
- 28 August 2023
- Published by Springer Nature
- p. 11-20
Solution
- 28 August 2023
- Published by Springer Nature
- p. 173-187
Spectrofluorimetry